Novo Nordisk stock trades down after mixed news on Wegovy in Singapore and Awiqli launch in India

Traders Union
All News
Financial News
Novo Nordisk slips 0.07% to $48.86

Highlights

Novo Nordisk updated Wegovy's label in Singapore with STEP UP trial data, likely boosting prescriber confidence and market access for its obesity therapy.
New launches in India and withdrawal of a CagriSema device study indicate sharpened focus on core GLP-1 assets within Novo Nordisk’s obesity pipeline.
NVO/USD shows short- and medium-term downside momentum, with expected near-term trading capped between $47.99 and $49.73 and rebound probability at just 25%.

Obesity franchise momentum as regulatory wins counter shifting development focus

Novo Nordisk has updated the Wegovy label in Singapore to include results from the STEP UP clinical trial for semaglutide in adults with obesity, reflecting clinically meaningful benefits reported in the study, according to Finance Yahoo. This regulatory advance may help improve prescriber confidence and market access for Wegovy in the local market, adding to the company’s obesity franchise. Novo Nordisk has also launched the once-weekly insulin injection Awiqli in India, aiming to expand patient access through competitive pricing, as reported by Ndtvprofit, while the withdrawal of its CagriSema device comparability study—cited by Tipranks—signals a sharper focus on the company’s core GLP-1 obesity assets.

Technical selling pressure as oversold signals clash with weak trend

On the H1 chart, NVO is positioned below the MA-20 at $49.22 and the MA-50 at $49.18, but remains above the longer-term MA-200, currently at $47.62 on the daily timeframe. The immediate resistance is noted at $49.47, reflecting the Ichimoku Kijun level. Bearish signals dominate momentum indicators, with both the Moving Average Convergence Divergence (MACD) and Relative Strength Index (RSI) suggesting selling conditions, while the Average Directional Index (ADX) indicates neutral trend strength. The Stochastic RSI is hovering in oversold territory and seller dominance is further supported by negative readings from the Commodity Channel Index (CCI) and Bull/Bear Power. The Awesome Oscillator remains neutral, not confirming a sustained trend direction. This technical setup highlights a divergence between oversold oscillators and persistent downside pressure, suggesting short-term indecision.

Limited upside likely as range persists after failed resistance tests

In the near term, NVO is expected to trade within a range of $47.99 to $49.73, aligning with recent volatility bands. The probability of a price rebound is relatively low, with a 25% chance of an upside move as compared to a 75% likelihood of continued pressure. The baseline scenario points to a sideways pattern unless resistance at $49.47 is decisively breached, which could open room for a bullish momentum shift. A downward scenario would unfold if price action slips below the $47.99 support, confirming a continuation of the current weak bias.

Anton Kharitonov, expert at Traders Union, sees Novo Nordisk balancing regulatory progress with cautious market sentiment. He notes new clinical data and product launches, but technical signals remain bearish. Momentum favors continued selling unless resistance at $49.47 is reclaimed. "Base case remains sideways to weak, and I stay on the defensive unless the price breaks clearly above $49.47."

Earlier, analysts noted that appetite-suppressing drugs like Wegovy have triggered rising demand and shifted healthcare and consumer behavior, particularly in markets with split access between private and public systems. Novo Nordisk's latest regulatory and commercial moves in Asia highlight the company's ongoing global expansion in obesity treatments, with current market dynamics suggesting that traders should monitor $49.47 as the key resistance level that could shift momentum from consolidation to recovery.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.